Get the Stockscreener App
1.56
7.14%
-0.12
After Hours:
1.59
0.03
+1.92%
Inhibikase Therapeutics Inc stock is traded at $1.56, with a volume of 78,545.
It is down -7.14% in the last 24 hours and down -10.86% over the past month.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.
See More
Previous Close:
$1.68
Open:
$1.68
24h Volume:
78,545
Relative Volume:
0.34
Market Cap:
$116.25M
Revenue:
-
Net Income/Loss:
$-19.57M
P/E Ratio:
-0.4984
EPS:
-3.13
Net Cash Flow:
$-17.24M
1W Performance:
-6.59%
1M Performance:
-10.86%
6M Performance:
-30.04%
1Y Performance:
+30.00%
1-Day Range:
$1.55
$1.68
1-Week Range:
$1.50
$1.73
52-Week Range:
$1.12
$4.20
Inhibikase Therapeutics Inc Stock (IKT) Company Profile
Name
Inhibikase Therapeutics Inc
Sector
Industry
Phone
(302) 295-3800
Address
1000 N. WEST STREET, SUITE 1200, WILMINGTON
Compare IKT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IKT
Inhibikase Therapeutics Inc
|
1.56 | 114.76M | 0 | -19.57M | -17.24M | -3.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Inhibikase Therapeutics Inc Stock (IKT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-12-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
Inhibikase Therapeutics Inc Stock (IKT) Latest News
Analyzing net buyer seller activity in Inhibikase Therapeutics Inc.Market Activity Summary & Free Daily Entry Point Trade Alerts - Newser
Inhibikase Therapeutics Inc. stock chart pattern explainedDay Trade & Technical Pattern Based Signals - Newser
Is Inhibikase Therapeutics Inc. building a consolidation base2025 Big Picture & Short-Term High Return Strategies - Newser
How hedge fund analytics apply to Inhibikase Therapeutics Inc. stockJuly 2025 Analyst Calls & Safe Capital Growth Plans - Newser
Will Inhibikase Therapeutics Inc. bounce back from current supportDay Trade & AI Powered Market Trend Analysis - Newser
Using AI based signals to follow Inhibikase Therapeutics Inc.Portfolio Performance Report & Pattern Based Trade Signal System - Newser
Backtesting results for Inhibikase Therapeutics Inc. trading strategiesWeekly Risk Report & Entry Point Confirmation Signals - Newser
Ranking Inhibikase Therapeutics Inc. among high performing stocks via toolsWeekly Stock Analysis & Weekly Top Gainers Trade List - Newser
Is Inhibikase Therapeutics Inc. still worth holding after the dipMarket Risk Analysis & Expert-Curated Trade Recommendations - Newser
Order flow analysis tools used on Inhibikase Therapeutics Inc.July 2025 Decliners & High Return Stock Watch Alerts - Newser
Relative strength of Inhibikase Therapeutics Inc. in sector analysisQuarterly Profit Summary & Real-Time Stock Movement Alerts - Newser
Inhibikase Therapeutics Inc. recovery potential after sell offOptions Play & Consistent Profit Focused Trading Strategies - Newser
What data driven models say about Inhibikase Therapeutics Inc.’s future2025 Top Decliners & AI Powered Trade Plan Recommendations - Newser
Can Inhibikase Therapeutics Inc. hit a new high this monthQuarterly Growth Report & Fast Gain Swing Alerts - Newser
what data driven models say about inhibikase therapeutics inc.’s futureMarket Weekly Review & Daily Risk Controlled Trade Plans - Newser
Using R and stats models for Inhibikase Therapeutics Inc. forecasting2025 Valuation Update & Precise Buy Zone Tips - Newser
What does recent volatility data suggest for Inhibikase Therapeutics Inc.New Guidance & Low Risk Entry Point Tips - Newser
Using RSI to spot recovery in Inhibikase Therapeutics Inc.July 2025 Fed Impact & Accurate Buy Signal Notifications - Newser
Published on: 2025-09-08 22:16:33 - Newser
Reversal indicators forming on Inhibikase Therapeutics Inc. stockEarnings Overview Report & Advanced Swing Trade Entry Plans - Newser
Is Inhibikase Therapeutics Inc. forming a reversal patternPortfolio Growth Summary & High Accuracy Swing Entry Alerts - Newser
Published on: 2025-09-08 14:58:04 - beatles.ru
Is Inhibikase Therapeutics Inc. likely to announce a buybackJuly 2025 Macro Moves & Capital Efficient Trading Techniques - beatles.ru
Measuring Inhibikase Therapeutics Inc.’s beta against major indicesRecession Risk & Verified Chart Pattern Trade Signals - Newser
Inhibikase Therapeutics Inc. Stock Approaches Key Moving Average2025 Performance Recap & Community Consensus Trade Signals - beatles.ru
Inhibikase Therapeutics Inc Stock (IKT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):